

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 960 110 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)
INID code(s) 54

(51) Int Cl.7: **C07D 487/04**, A61K 31/505
// (C07D487/04, 239:00,
231:00)

(48) Corrigendum issued on:

27.11.2002 Bulletin 2002/48

(86) International application number:

PCT/US97/24172

(45) Date of publication and mention
of the grant of the patent:

20.03.2002 Bulletin 2002/12

(87) International publication number:

WO 98/029413 (09.07.1998 Gazette 1998/27)

(21) Application number: **97954301.4**

(22) Date of filing: **23.12.1997**

(54) **3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES;
CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS**

3-ARYL PYRAZOLO[4,3-D]PYRIMIDIN DERIVATE; CORTICOTROPIN
AUSLÖSEFAKTOR-REZEPTOR (CRF1) SPEZIFISCHE LIGANDEN

DERIVES DE PYRAZOLO[4,3-D]PYRIMIDINE A SUBSTITUTION ARYLE EN POSITION 3;
LIGANDS SPECIFIQUES AU RECEPTEUR DE FACTEUR LIBERATEUR DE CORTICOTROPHINE
(CRF1)

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(56) References cited:

EP-A- 0 691 128 WO-A-94/13677
WO-A-95/33750 WO-A-96/35689
WO-A-97/29109

(30) Priority: **31.12.1996 US 775404**

(43) Date of publication of application:

01.12.1999 Bulletin 1999/48

(73) Proprietor: **NEUROGEN CORPORATION**

Branford, CT 06405 (US)

(72) Inventor: **YUAN, Jun**

Guilford, CT 06437 (US)

(74) Representative: **Vossius, Volker, Dr. et al**

Dr. Volker Vossius,
Patentanwaltskanzlei - Rechtsanwaltskanzlei,
Geibelstrasse 6
81679 München (DE)

- **H TAKEI ET AL: "A new synthetic method for some Pyrazolo[4,3-d]pyrimidines" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 52, no. 1, 1979, TOKYO, pages 208-211, XP002062574 cited in the application**
- **J AVILA ET AL: "Biological action of pyrazolopyrimidine derivatives against Trypanosoma cruzi" COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C, COMPARATIVE PHARMACOLOGY AND TOXICOLOGY, vol. 74, no. 1, 1993, LONDON, pages 49-54, XP002062575**
- **M J OWENS ET AL: "Physiology and pharmacology of Corticotropin-releasing factor" PHARMACOLOGICAL REVIEWS, vol. 43, no. 4, 1991, USA, pages 425-473, XP000614410**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 960 110 B8